A pilot study examining short-term changes in bone mineral density among class 3 obese users of depot-medroxyprogesterone acetate

REFERENCES

• Kraak V, Story M. A public health perspective on healthy lifestyles and public–private partnerships for global childhood obesity prevention. J Am Diet Assoc 2010;110: 192–200.
   PubMed Web of Science ®Google Scholar
• Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight. and obesity in adults: Executive summary. Am J Clin Nutr 1998;68:899–917.
   PubMed Web of Science ®Google Scholar
• Cedergren M. Maternal morbid obesity and the risk of adverse pregnancy outcomes. Obstet Gynecol 2004;103: 219–24.
   PubMed Web of Science ®Google Scholar
• Segall-Gutierrez P, Taylor D, Liu X, et al. Follicular development and ovulation in extremely obese women receiving depot-medroxyprogesterone acetate subcutaneously. Contraception 2010;81:487–95.
   PubMed Web of Science ®Google Scholar
• Guilbert E, Kaunitz AM. Depo-Provera and skeletal health: Reviewing the evidence; developing and disseminating a consensus. Contraception 2009;79:165–6.
   PubMed Web of Science ®Google Scholar
• Kirchengast S, Knogler W, Hauser G. Protective effect of moderate overweight on bone density of the hip joint in elderly and old Austrians. Anthropol Anz 2002; 60:187–97.
   PubMedGoogle Scholar
• Ribot C, Trémollières F, Pouillès JM. The effect of obesity on postmenopausal bone loss and the risk of osteoporosis. Adv Nutr Res 1994;9:257–71.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use, 4th edn. Geneva: World Health Organization 2010. Accessed 23 December 2012 from: http://whqlibdoc.who.int/publications/2010/9789241563888_eng.pdf
   Google Scholar
• Hologic QDR 4500 QDR for Windows. Fan Bean X-Ray Bone Densitometer - Technical Manual. Bedford, MA, 2000:1–2.
   Google Scholar
• Harel Z, Wolter K, Gold MA, et al. Biopsychosocial variables associated with substantial bone mineral density loss during the use of depot medroxyprogesterone acetate in adolescents: Adolescents who lost 5% or more from baseline vs. those who lost less than 5%. Contraception 2010;82:503–12.
   PubMed Web of Science ®Google Scholar
• Costa Paiva L, Pinto-Neto AM, Faundes A. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive. Contraception 1998;58:351–5.
   PubMed Web of Science ®Google Scholar
• Meier C, Brauchli YB, Jick SS, et al. Use of depomedroxyprogesterone acetate and fracture risk. J Clin Endocrinol Metab 2010;95:4909–16.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception 2008;77:67–76.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM, Miller PD, Rice VM, et al. Bone mineral density in women aged 25–35 receiving depot medroxyprogesterone acetate: Recovery following discontinuation. Contraception 2006;74:90–9.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Beck E, De Flines J, Rorive M. Obesity, insulin resistance and type 2 diabetes: Risk factors for breast cancer. Rev Med Liege 2011;66:238–44.
   PubMedGoogle Scholar
• Cundy T, Evans M, Roberts H, et al. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ 1991;303:13–6.
   PubMed Web of Science ®Google Scholar
• Slemenda C, Longcope C, Peacock M, et al. Sex steroids, bone mass, and bone loss: A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 1996; 97:14–21.
   PubMed Web of Science ®Google Scholar
• Rahman M, Berenson AB. Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate. Obstet Gynecol 2010;115:35–40.
   PubMed Web of Science ®Google Scholar
• Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril 2004; 82:1580–6.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). U.S. medical eligibility criteria for contraceptive use, 2010: adapted from the World Health Organization medical eligibility criteria for contraceptive use, 4th edn. Atlanta, GA: Centers for Disease Control and Prevention 2010:1–86.
   Google Scholar
• Faculty of Sexual and Reproductive Healthcare (FSRH). UK medical eligibility criteria for contraceptive use, 2009. Accessed 19 January 2013 from: http://www.fsrh.org/pdfs/UKMEC2009.pdf
   Google Scholar
• American College of Obstetricians and Gynecologists (ACOG). Use of hormonal contraception in women with coexisting medical conditions. Washington, DC: American College of Obstetricians and Gynecologists (ACOG) 2006 (ACOG practice bulletin; no. 73). Accessed 19 January 2013 from: http://www.guidelines.gov/content.aspx?id = 10924
   Google Scholar